In CT26 tumor bearing mice, gemcitabine enhanced 89Zr-anti-PD-L1 tumor uptake from 1.56 ± 0.48 % to 6.24 ± 0.37 % of the injected dose/g (Jung et al., 2021). This evidence concerns the gene CD274 and neoplasm.